Open AccessMP29‐02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
Author(s) -
Scadding Glenis,
Bachert Claus,
Hellings Peter,
Fokkens Wytske,
Munzel Ullrich,
Mösges Ralph
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s4-p36
Subject(s) - medicine , fluticasone propionate , post hoc analysis , placebo , asthma , pathology , alternative medicine
Background Four previously published trials assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) in seasonal allergic rhinitis (SAR) [1,2]. The first study compared MP29-02* to marketed AZE and FP [2]. The others compared MP29-02* to AZE and FP in the MP29-02* vehicle and delivery device (i.e. re-formulated comparators) [1]. FP contained within MP29-02* has a unique PK fingerprint [3]. The aim of this analysis was to demonstrate that formulation/device contribute to MP29-02*’s clinical efficacy.